Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure

Campbell P. Cross, Selena Liao, Zachary D. Urdang, Priya Srikanth, Angela C. Garinis, Peter Steyger

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objectives: Hearing loss in neonatal intensive care unit (NICU) graduates range from 2% to 15% compared to 0.3% in full-term births, and the etiology of this discrepancy remains unknown. The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis. Endotoxemia and inflammation are associated with increased cochlear uptake of aminoglycosides and potentiated ototoxicity in mice. We tested the hypothesis that sepsis or systemic inflammatory response syndrome (SIRS) and intravenous gentamicin exposure increases the risk of hearing loss in NICU admissions. Methods: The Institutional Review Board at Oregon Health & Science University (OHSU) approved this study design. Two hundred and eight infants met initial criteria, and written, informed consent were obtained from parents or guardians of 103 subjects ultimately enrolled in this study. Prospective data from 91 of the enrolled subjects at OHSU Doernbecher Children's Hospital Neonatal Care Center were processed. Distortion product otoacoustic emissions (DPOAEs; f2 frequency range: 2063-10,031. Hz) were obtained prior to discharge to assess auditory performance. To pass the DPOAE screen, normal responses in >6 of 10 frequencies in both ears were required; otherwise the subject was considered a "referral" for a diagnostic hearing evaluation after discharge. Cumulative dosing data and diagnosis of neonatal sepsis or SIRS were obtained from OHSU's electronic health record system, and the data processed to obtain risk ratios. Results: Using these DPOAE screening criteria, 36 (39.5%) subjects would be referred. Seventy-four (81%) subjects had intravenous gentamicin exposure. Twenty (22%) had ≥4 days of gentamicin, and 71 (78%) had

Original languageEnglish (US)
JournalInternational Journal of Pediatric Otorhinolaryngology
DOIs
StateAccepted/In press - Aug 6 2015

Fingerprint

Neonatal Screening
Systemic Inflammatory Response Syndrome
Gentamicins
Hearing
Neonatal Intensive Care Units
Sepsis
Aminoglycosides
Hearing Loss
Term Birth
Endotoxemia
Electronic Health Records
Research Ethics Committees
Cochlea
Informed Consent
Information Systems
Ear
Referral and Consultation
Parents
Odds Ratio
Inflammation

Keywords

  • Aminoglycosides
  • DPOAE
  • Gentamicin
  • Ototoxicity
  • Sepsis
  • SIRS

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Pediatrics, Perinatology, and Child Health

Cite this

Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure. / Cross, Campbell P.; Liao, Selena; Urdang, Zachary D.; Srikanth, Priya; Garinis, Angela C.; Steyger, Peter.

In: International Journal of Pediatric Otorhinolaryngology, 06.08.2015.

Research output: Contribution to journalArticle

@article{00d9ddd6f8ef49828373e5e3caf2da93,
title = "Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure",
abstract = "Objectives: Hearing loss in neonatal intensive care unit (NICU) graduates range from 2{\%} to 15{\%} compared to 0.3{\%} in full-term births, and the etiology of this discrepancy remains unknown. The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis. Endotoxemia and inflammation are associated with increased cochlear uptake of aminoglycosides and potentiated ototoxicity in mice. We tested the hypothesis that sepsis or systemic inflammatory response syndrome (SIRS) and intravenous gentamicin exposure increases the risk of hearing loss in NICU admissions. Methods: The Institutional Review Board at Oregon Health & Science University (OHSU) approved this study design. Two hundred and eight infants met initial criteria, and written, informed consent were obtained from parents or guardians of 103 subjects ultimately enrolled in this study. Prospective data from 91 of the enrolled subjects at OHSU Doernbecher Children's Hospital Neonatal Care Center were processed. Distortion product otoacoustic emissions (DPOAEs; f2 frequency range: 2063-10,031. Hz) were obtained prior to discharge to assess auditory performance. To pass the DPOAE screen, normal responses in >6 of 10 frequencies in both ears were required; otherwise the subject was considered a {"}referral{"} for a diagnostic hearing evaluation after discharge. Cumulative dosing data and diagnosis of neonatal sepsis or SIRS were obtained from OHSU's electronic health record system, and the data processed to obtain risk ratios. Results: Using these DPOAE screening criteria, 36 (39.5{\%}) subjects would be referred. Seventy-four (81{\%}) subjects had intravenous gentamicin exposure. Twenty (22{\%}) had ≥4 days of gentamicin, and 71 (78{\%}) had",
keywords = "Aminoglycosides, DPOAE, Gentamicin, Ototoxicity, Sepsis, SIRS",
author = "Cross, {Campbell P.} and Selena Liao and Urdang, {Zachary D.} and Priya Srikanth and Garinis, {Angela C.} and Peter Steyger",
year = "2015",
month = "8",
day = "6",
doi = "10.1016/j.ijporl.2015.09.004",
language = "English (US)",
journal = "International Journal of Pediatric Otorhinolaryngology",
issn = "0165-5876",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Effect of sepsis and systemic inflammatory response syndrome on neonatal hearing screening outcomes following gentamicin exposure

AU - Cross, Campbell P.

AU - Liao, Selena

AU - Urdang, Zachary D.

AU - Srikanth, Priya

AU - Garinis, Angela C.

AU - Steyger, Peter

PY - 2015/8/6

Y1 - 2015/8/6

N2 - Objectives: Hearing loss in neonatal intensive care unit (NICU) graduates range from 2% to 15% compared to 0.3% in full-term births, and the etiology of this discrepancy remains unknown. The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis. Endotoxemia and inflammation are associated with increased cochlear uptake of aminoglycosides and potentiated ototoxicity in mice. We tested the hypothesis that sepsis or systemic inflammatory response syndrome (SIRS) and intravenous gentamicin exposure increases the risk of hearing loss in NICU admissions. Methods: The Institutional Review Board at Oregon Health & Science University (OHSU) approved this study design. Two hundred and eight infants met initial criteria, and written, informed consent were obtained from parents or guardians of 103 subjects ultimately enrolled in this study. Prospective data from 91 of the enrolled subjects at OHSU Doernbecher Children's Hospital Neonatal Care Center were processed. Distortion product otoacoustic emissions (DPOAEs; f2 frequency range: 2063-10,031. Hz) were obtained prior to discharge to assess auditory performance. To pass the DPOAE screen, normal responses in >6 of 10 frequencies in both ears were required; otherwise the subject was considered a "referral" for a diagnostic hearing evaluation after discharge. Cumulative dosing data and diagnosis of neonatal sepsis or SIRS were obtained from OHSU's electronic health record system, and the data processed to obtain risk ratios. Results: Using these DPOAE screening criteria, 36 (39.5%) subjects would be referred. Seventy-four (81%) subjects had intravenous gentamicin exposure. Twenty (22%) had ≥4 days of gentamicin, and 71 (78%) had

AB - Objectives: Hearing loss in neonatal intensive care unit (NICU) graduates range from 2% to 15% compared to 0.3% in full-term births, and the etiology of this discrepancy remains unknown. The majority of NICU admissions receive potentially ototoxic aminoglycoside therapy, such as gentamicin, for presumed sepsis. Endotoxemia and inflammation are associated with increased cochlear uptake of aminoglycosides and potentiated ototoxicity in mice. We tested the hypothesis that sepsis or systemic inflammatory response syndrome (SIRS) and intravenous gentamicin exposure increases the risk of hearing loss in NICU admissions. Methods: The Institutional Review Board at Oregon Health & Science University (OHSU) approved this study design. Two hundred and eight infants met initial criteria, and written, informed consent were obtained from parents or guardians of 103 subjects ultimately enrolled in this study. Prospective data from 91 of the enrolled subjects at OHSU Doernbecher Children's Hospital Neonatal Care Center were processed. Distortion product otoacoustic emissions (DPOAEs; f2 frequency range: 2063-10,031. Hz) were obtained prior to discharge to assess auditory performance. To pass the DPOAE screen, normal responses in >6 of 10 frequencies in both ears were required; otherwise the subject was considered a "referral" for a diagnostic hearing evaluation after discharge. Cumulative dosing data and diagnosis of neonatal sepsis or SIRS were obtained from OHSU's electronic health record system, and the data processed to obtain risk ratios. Results: Using these DPOAE screening criteria, 36 (39.5%) subjects would be referred. Seventy-four (81%) subjects had intravenous gentamicin exposure. Twenty (22%) had ≥4 days of gentamicin, and 71 (78%) had

KW - Aminoglycosides

KW - DPOAE

KW - Gentamicin

KW - Ototoxicity

KW - Sepsis

KW - SIRS

UR - http://www.scopus.com/inward/record.url?scp=84941750905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941750905&partnerID=8YFLogxK

U2 - 10.1016/j.ijporl.2015.09.004

DO - 10.1016/j.ijporl.2015.09.004

M3 - Article

C2 - 26384832

AN - SCOPUS:84952637690

JO - International Journal of Pediatric Otorhinolaryngology

JF - International Journal of Pediatric Otorhinolaryngology

SN - 0165-5876

ER -